Brief: AIM Immunotech Announces Authorizations To Begin A Phase 1B/2 Study For The Treatment Of Pancreatic Cancer
27/06/2023 15:12
June 27 (Reuters) - AIM ImmunoTech Inc AIM.A :
* AIM IMMUNOTECH ANNOUNCES AUTHORIZATIONS FROM COMPETENT
AUTHORITY
AND ETHICS BOARD IN THE NETHERLANDS TO BEGIN A PHASE 1B/2 STUDY
EVALUATING AMPLIGEN® (RINTATOLIMOD) IN COMBINATION WITH
ASTRAZENECA’S IMFINZI (DURVALUMAB) FOR THE TREATMENT OF
PANCREATIC CANCER
Source text for Eikon: ID:nGNE6Fy1kX
Further company coverage: AIM.A
Recent news on AIM ImmunoTech
See all newsBrief: Aim Immunotech Duripanc Primary Endpoint Analysis To Begin December 2026 Topline Results Expected Q1 2027
Brief: Aim Immunotech Files To Offer And Resell Up To 13.08 Million Shares Of Common Stock By Selling Stockholders
Brief: AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market Under NYSE American Rules
Brief: Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027
Brief: Aim Immunotech Announces 50% Objective Response Rate (Orr) In Upmc Recurrent Ovarian Cancer Phase 2 Clinical Trial, Suggesting Breakthrough Combination Potential